Fluorescent Intra-operative Tumor Margin Examination

Description

Tumor margin confirmation is important to confirming appropriate disease excision. Current standard of care is to take select margin samples to pathology for intra-operative readings. However, this is expensive, time consuming, and only assesses the margin contained within the specific sample. In prior work the investigators have determined that indocyanine green (ICG) is highly specific to the tumor bed when injected shortly before surgery. The investigators hypothesize that ICG will be able to accurately identify residual positive tumor margins during sarcoma excision procedures.

Conditions

Sarcoma

Study Overview

Study Details

Study overview

Tumor margin confirmation is important to confirming appropriate disease excision. Current standard of care is to take select margin samples to pathology for intra-operative readings. However, this is expensive, time consuming, and only assesses the margin contained within the specific sample. In prior work the investigators have determined that indocyanine green (ICG) is highly specific to the tumor bed when injected shortly before surgery. The investigators hypothesize that ICG will be able to accurately identify residual positive tumor margins during sarcoma excision procedures.

Evaluation of Intraoperative Tumor Margin Identification With Fluorescent Dye Imaging

Fluorescent Intra-operative Tumor Margin Examination

Condition
Sarcoma
Intervention / Treatment

-

Contacts and Locations

Pittsburgh

Alma E Heyl, Pittsburgh, Pennsylvania, United States, 15232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients above the age of 18 with a primary musculoskeletal tumor that has been indicated for surgical excision by a fellowship trained orthopaedic oncologist.
  • * Surgical consent was obtained prior to research consent.
  • * Patients with a biopsy-confirmed primary soft tissue or bone tumor that has not been previously excised and has a known risk of local or remote recurrence.
  • * Patients below the age of 18
  • * Pregnancy, breast feeding
  • * Patients with a history of anaphylactic reaction to contrast media or fluorescein allergy
  • * Prior surgery local to the mass being excised
  • * Non- or minimally-recurrent masses (i.e. osteochondroma)
  • * Dialysis, renal failure, uremia

Ages Eligible for Study

18 Years to 100 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Kurt Weiss,

Kurt E Weiss, PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Study Record Dates

2025-06